Invion Limited (ASX:IVX – Get Free Report) insider Chiat Chew bought 17,861,942 shares of the company’s stock in a transaction on Wednesday, September 4th. The stock was purchased at an average cost of A$0.00 ($0.00) per share, for a total transaction of A$35,723.88 ($23,815.92).
Invion Stock Performance
About Invion
Invion Limited, a clinical-stage life-sciences company, researches and develops Photosoft technology for the treatment of various cancers, atherosclerosis, and infectious diseases in Australia. The company is developing IVX-PDT, a photosensitizer agent to treat skin cancers, as well as solid cancers, including lung, prostrate, ovarian, anogenital, and mesothelioma cancers.
Featured Articles
- Five stocks we like better than Invion
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Matador Resources Insiders Keep Buying Its Stock, Should You?
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Oracle Can Turn the Magnificent 7 Into 8: Here’s Why
- Stock Splits, Do They Really Impact Investors?
- Palantir Stock Is Up 14% on S&P 500 News: Is It Time to Buy?
Receive News & Ratings for Invion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invion and related companies with MarketBeat.com's FREE daily email newsletter.
